Have a personal or library account? Click to login
The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet Cover

The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet

Open Access
|Apr 2020

References

  1. Abozguia K, Chudley S, Gammage M. (2006). Dose-dependent Venlafaxine-induced sinus tachycardia. Int J Cardiol113: E9–10.10.1016/j.ijcard.2006.01.072
  2. Alosaimi FD, Abalhassan M, Alhaddad B, Alzain N, Fallata E, Alhabbad A, Alassiry MZ. (2017). Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: A cross-sectional study. Gen Hosp Psychiatry45: 62–69.10.1016/j.genhosppsych.2016.12.007
  3. Bavle A. (2015). Venlafaxine induced QTc interval prolongation in a therapeutic dose. Asian J Psychiatr16: 63–64.10.1016/j.ajp.2015.06.001
  4. Bilora F, Vettore G, Barbata A, Pastorello M, Petrobelli F, San Lorenzo I. (1999). Electrocardiographic findings in obese subjects. Minerva Gastroenterol Dietol45: 193–197.
  5. Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. (2005). Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. J Hypertens23: 1241–9.10.1097/01.hjh.0000170388.61579.4f
  6. Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, Cros G, Azay J. (2005). Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis179: 43–49.10.1016/j.atherosclerosis.2004.10.018
  7. Dupas J, Feray A, Goanvec C, Guernec A, Samson N, Bougaran P, Guerrero F, Mansourati J. (2017). Metabolic Syndrome and Hypertension Resulting from Fructose Enriched Diet in Wistar Rats. Biomed Res Int2017: 2494067.10.1155/2017/2494067
  8. Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, Liesa M, Shirihai OS, Rimer J, Schaffer JE, Colucci WS, Miller EJ. (2015). Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload. J Mol Cell Cardiol79: 275–283.10.1016/j.yjmcc.2014.12.001
  9. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). (2011). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet377: 557–567.10.1016/S0140-6736(10)62037-5
  10. Flegal KM, Graubard BI, Williamson DF, Gail MH. (2007). Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA298: 2028–2037.10.1001/jama.298.17.2028
  11. Gancheva S, Galunska B, Zhelyazkova-Savova M. (2017). Diets rich in saturated fat and fructose induce anxiety and depression-like behaviors in the rat: is there a role for lipid peroxidation? Int J Exp Pathol98: 296–306.10.1111/iep.12254574378729210119
  12. Gariepy G, Nitka D, Schmitz N. (2010). The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int J Obes (Lond)34: 407–419.10.1038/ijo.2009.252
  13. Gradel AKJ, Salomonsson M, Sørensen CM, Holstein-Rathlou NH, Jensen LJ. (2018). Long-term diet-induced hypertension in rats is associated with reduced expression and function of small artery SKCa, IKCa, and Kir2.1 channels. Clin Sci (Lond)132: 461–474.10.1042/CS20171408
  14. Harvey AT, Rudolph RL, Preskorn SH. (2000). Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry57: 503–509.10.1001/archpsyc.57.5.503
  15. Hinderliter AL, Sherwood A, Craighead LW, Lin PH, Watkins L, Babyak MA, Blumenthal JA. (2014). The long-term effects of lifestyle change on blood pressure: One-year follow-up of the ENCORE study. Am J Hypertens 27: 734–741.10.1093/ajh/hpt183
  16. Howarth FC, Jacobson M, Shafiullah M, Adeghate E. (2008). Long-term effects of type 2 diabetes mellitus on heart rhythm in the Goto-Kakizaki rat. Exp Physiol93: 362–369.10.1113/expphysiol.2007.040055
  17. Cheng S-M, Cheng Y-J, Wu L-Y, Kuo C-H, Lee Y-S, Wu M-C, Huang C-Y, Ting H, Lee S-D. (2014). Activated apoptotic and anti-survival effects on rat hearts with fructose induced metabolic syndrome. Cell Biochem Funct32: 133–141.10.1002/cbf.2982
  18. Jover B, Reynes C, Rugale C, Reboul C, Jeanson L, Tournier M, Lajoix AD, Desmetz C. (2017). Sodium restriction modulates and prevents cardiac remodeling in a rat model of Metabolic syndrome. Biochim Biophys Acta Mol Basis Dis1863: 1568–1574.10.1016/j.bbadis.2017.02.026
  19. Kaprinay B, Lipták B, Slovák L, Švík K, Knezl V, Sotníkoví R, Gáspárová Z. (2016). Hypertriglyceridemic rats fed high fat diet as a model of metabolic syndrome. Physiol Res65: S515–S518.10.33549/physiolres.933524
  20. Kaprinay B, Gáspárová Z, Lipták B, Frimmel K, Sotníková R. (2017). Endothelial dysfunction in experimental models of metabolic syndrome - effect of fructose. Eur Pharm J64: 4–6.10.1515/afpuc-2017-0014
  21. Khalifa M, Daleau P, Turgeon J. (1999). Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther291: 280–284.
  22. Khurana RN, Baudendistel TE. (2003). Hypertensive crisis associated with venlafaxine. Am J Med115: 676–677.10.1016/S0002-9343(03)00472-8
  23. Kıvrak Y, Güvenç TS, Akbulut N, Yağcı I, Çığşar G, Gündüz S, Balcı B. (2014). Accelerated Hypertension after Venlafaxine Usage. Case Rep Psychiatry2014: 659715.10.1155/2014/659715
  24. Knezl V, Sotní ková R, Brnoliaková Z, Stankovič ová T, Bauer V, Bezek Š. (2017). Monotherapy of experimental metabolic syndrome: II. study of cardiovascular effects. Interdiscip Toxicol10: 86–92.10.1515/intox-2017-0014
  25. Kurl S, Laaksonen DE, Jae SY, Makikallio TH, Zaccardi F, Kauhanen J, Ronkainen K, Laukkanen JA. (2015). Metabolic syndrome and the risk of sudden cardiac death in middle-aged men. Int J Cardiol203: 792–797.10.1016/j.ijcard.2015.10.218
  26. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. (2006). QT interval prolongation associated with venlafaxine administration. Int J Cardiol109: 116–117.10.1016/j.ijcard.2005.03.065
  27. Li W, Bai Y, Sun K, Xue H, Wang Y, Song X, Fan X, Song H, Han Y, Hui R. (2009). Patients with metabolic syndrome have prolonged corrected QT interval (QTc). Clin Cardiol32: E93–99.10.1002/clc.20416
  28. Lipták B, Kaprinay B, Gáspárová Z. (2017a). A rat-friendly modification of the non-invasive tail-cuff to record blood pressure. Lab Animal46: 251–253.10.1038/laban.127228530692
  29. Mbaya P, Alam F, Ashim S, Bennett D. (2007). Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Human Psychopharmacology22: 129–133.10.1002/hup.834
  30. McIntyre RS, Young Park K, Law CWY, Sultan F, Adams A, Lourenco MT, Lo AKS, Soczynska JK, Woldeyohannes H, Alsuwaidan M, Yoon J, Kenedy SH. (2010). The association between conventional antidepressants and the metabolic syndrome. CNS Drugs24: 741–753.10.2165/11533280-000000000-00000
  31. Moro C, Cosío FG. (1980). Electrophysiologic study of patients with short P-R interval and normal QRS complex. Eur J Cardiol11: 81–90.
  32. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB. (2012). Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35: 1171–1180.10.2337/dc11-2055
  33. Sasváriová M, Tyukos-Kaprinay B, Salvaras L, Belovičová K, Bögi E, Knezl V, Barteková M, Stankovičová T, Dubovický M. (2018). Effect of pre-gestational stress and prenatal venlafaxine administration on cardiovascular system of rat offspring. Eur Pharm J65: 17–22.10.2478/afpuc-2018-0007
  34. Schumacher K, Büttner P, Dagres N, Sommer P, Dinov B, Hindricks G, Bollmann A, Kornej J. (2018). Association between PR interval prolongation and electro-anatomical substrate in patients with atrial fibrillation. PLoS One13: e0206933.10.1371/journal.pone.0206933
  35. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, Kessler RC. (2006). Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry63: 824–830.10.1001/archpsyc.63.7.824
  36. Toscano AE, Amorim MA, de Carvalho Filho EV, Aragão Rda S, Cabral-Filho JE, de Moraes SR, Manhaes-de-Castro R. (2008). Do malnutrition and fluoxetine neonatal treatment program alterations in heart morphology? Life Sci82: 21–22.10.1016/j.lfs.2008.03.01318445498
  37. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. (2011). Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res92: 10–18.10.1093/cvr/cvr212
  38. Vicen M, Gulač P, Stankovičová T. (2016). Changes in electrical activity of heart during ischemic-reperfusion injury modified by the administration of antidepressants. Eur Pharm J1: 5–8.10.1515/afpuc-2016-0006
  39. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchaell AJ, De Herdt A, Probst M, Scheewe W, De Hert M. (2014). Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalence and moderating variables. Psychol Med44: 2017–2028.10.1017/S0033291713002778
  40. Watanabe H., Tanabe N, Watanabe T, Roden D M, Sasaki S. (2008). Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation. Circulation117: 1255–1260.10.1161/CIRCULATIONAHA.107.744466
  41. Wong SK, Chin KY, Suhaimi FH, Ahmad F, Ima-Nirwana S. (2018). The Effects of a Modified High-carbohydrate High-fat Diet on Metabolic Syndrome Parameters in Male Rats. Exp Clin Endocrinol Diabetes 126: 205–212.10.1055/s-0043-119352
  42. Yang Q, Kiyoshige K, Fujimoto T, Katayama M, Fujino K, Saito K, Nakaya Y, Mori H. (1990). Signal-averaging electrocardiogram in patients with diabetes mellitus. Jpn Heart J31: 25–33.10.1536/ihj.31.25
  43. Yilmaz H1, Özcan KS, Sayar N, Kemaloglu T, Gungor B, Erer B, Yilmaz M, Gurkan U, Cakmak N, Oz D, Calik AN, Bolca O. (2015). Metabolic syndrome is associated with atrial electrical and mechanical dysfunction. Med Princ Pract24: 147–152.10.1159/000368754
DOI: https://doi.org/10.2478/intox-2019-0024 | Journal eISSN: 1337-9569 | Journal ISSN: 1337-6853
Language: English
Page range: 192 - 199
Submitted on: Aug 14, 2019
Accepted on: Dec 20, 2019
Published on: Apr 30, 2020
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Michaela Sasváriová, Dominika Micháliková, Barbara Tyukos Kaprinay, Lazaros Salvaras, Slavomila Hričáková, Vladimír Knezl, Zdenka Gáspárová, Tatiana Stankovičová, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.